<DOC>
	<DOCNO>NCT01418495</DOCNO>
	<brief_summary>This research trial study Ch14.18 act body young patient high-risk neuroblastoma . Studying sample blood patient cancer receive Ch14.18 may help doctor learn drug use body develop good way give drug potentially improve effectiveness lessen side effect .</brief_summary>
	<brief_title>Pharmacokinetics Ch14.18 Younger Patients With High-Risk Neuroblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Describe pharmacokinetics ch14.18 ( monoclonal antibody Ch14.18 ) child high-risk neuroblastoma . II . Quantify degree inter-patient intra-patient variability clearance ch14.18 , correlate ch14.18 clearance patient characteristic , presence human anti-chimeric antibody ( HACA ) , tumor burden ( assessed scan ) , plasma GD2 level identify source variability clearance . III . Develop pharmacokinetic model describe pharmacokinetic profile ch14.18 derive pharmacokinetic ( PK ) parameter . SECONDARY OBJECTIVES : I. Correlate plasma concentration ch14.18 severity neuropathic pain , quantify use observational pain scale , total dose morphine administer control pain . II . Develop limit sample strategy accurately quantify area curve ( AUC ) ch14.18 . III . Simulate alternative dosing strategy pharmacokinetic model order reduce variability simplify drug administration . OUTLINE : Patients undergo blood sample collection baseline course 1 , 3 , 5 treatment pharmacokinetic analysis . Some patient undergo blood sample collection baseline two treatment course ( 1 3 , 1 5 , 3 5 ) .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>Diagnosis highrisk neuroblastoma Enrolled COG protocol ANBL0032 ANBL0931 eligible receive ch14.18 accord criterion primary treatment protocol Parental inform consent verbal assent subject appropriate Prior test demonstrate presence HACA Anaphylactic reaction ch14.18 prior treatment cycle</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>